The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo's Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples
Read MoreFunds will be used to bring the Amplified Lateral Flow (ALF) COVID-19 at-home rapid test through regulatory approval and to market, increase manufacturing capabilities, and advance the development of a range of new tests to significantly improve the diagnosis of the world's most prevalent and deadly diseases
Read More